Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab

Fig. 3

Regorafenib-Avelumab treatment triggers an immune response in cold soft-tissue sarcoma patients. a Flow chart illustrates the strategy used to identify biomarkers linked with Regorafenib-Avelumab treatment. Plasma samples collected at baseline and Cycle2 Day1 (C2D1) were analyzed using the Olink Explore HT panel. b Volcano plot showcases the differential protein expression in sarcoma patients upon treatment. c Boxplot representation of soluble CD274 (PD-L1) protein secretion. d Network visualization of GO term enrichment in patients treated with Regorafenib-Avelumab (left) and characterization of each identified cluster by text-mining (right). e Heatmap of immune cell estimation calculated by gsva in sarcoma patients upon treatment with Regorafenib and avelumab. f Boxplot representation of CD8+ T cells and B cells estimated proportions. P values were calculated using the Wilcoxon tests

Back to article page